Pipeline Maturity is Redefining Valuations in Biotech
The biotechnology industry is going through a transformation that is redefining how a company’s value is interpreted. While revenue has traditionally been highly associated with a company’s valuation, clinical-stage progression and a company’s probability of success are being increasingly factored into its valuation. Companies on the front lines of this shift, such as Oncotelic Therapeutics, are leveraging their expertise in the space, and showing how scientific advancement can influence financial positioning. The biotechnology sector is undergoing a meaningful shift in how companies are evaluated, challenging long-standing assumptions about value creation. Traditionally, valuation has been closely tied to revenue generation and…
